Takeda to acquire TiGenix7 Jan 2018
Acquisition will expand Takeda’s late-stage pipeline and leadership in gastroenterology.
Takeda has announced its intention to acquire TiGenix, an advanced biopharmaceutical company developing novel stem cell therapies for serious medical conditions, and as a result has entered into an offer and support agreement with TiGenix which provides for a recommended potential voluntary public takeover bid for TiGenix. The Takeda agreement has the unanimous support of the TiGenix board of directors (including its CEO). The acquisition is a natural extension of an existing partnership agreement between Takeda and TiGenix, which aims to bring new treatment options to patients with gastrointestinal disorders.
“As a leader in gastroenterology, Takeda recognizes the complex physical, emotional and social barriers that people living with fistulizing Crohn’s disease experience,” said Andrew Plump, Chief Medical and Scientific Officer, Takeda. “Limited treatment options exist today and I believe we can be most effective in serving this population by working in collaboration with partners whose unique skill sets allow us to more efficiently explore innovative approaches, including stem cell therapies. I have had the opportunity to work alongside the TiGenix team throughout our collaboration and know that we have shared goals and varied, but complementary expertise. I am thrilled at the prospect of welcoming them as part of our organization.”
In July 2016, Takeda and TiGenix entered into an exclusive ex-US license, development and commercialization agreement for Cx601, the leading investigational therapy in TiGenix’s pipeline. Cx601 is a suspension of allogeneic expanded adipose-derived stem cells (eASC) locally administered for the treatment of complex perianal fistulas in patients with non-active/mildly active luminal Crohn’s disease, who have had an inadequate response to at least one conventional or biologic therapy. In December 2017, the CHMP of the EMA adopted a positive opinion recommending a marketing authorization for Cx601 in this indication, the first allogeneic stem cell therapy to achieve this. A decision from the EMA on the marketing authorization for Cx601 is expected in the first half of 2018.
Complex perianal fistulas are considered one of the most disabling manifestations of Crohn’s disease and can cause intense pain, infection and incontinence. Despite modern and surgical advancements, they currently remain challenging for clinicians to treat and can have a severe impact on the lives of those affected.
A global, pivotal Phase III trial investigating Cx601 for the treatment of complex perianal fistulas in patients with non-active/mildly active luminal Crohn’s disease has been initiated for US registration. In the US, Takeda intends to work with the FDA to facilitate the development and potential approval of Cx601. Takeda is also exploring the steps required for regulatory filing of Cx601 for patients in Japan, Canada and emerging markets.
Through the potential voluntary public takeover bid, Takeda intends to acquire 100% of the securities with voting rights or giving access to voting rights of TiGenix not already owned by Takeda or its affiliates at an acquisition price of EUR 1.78 per share in cash and an equivalent price per American Depositary Share, warrant and convertible bond, representing a transaction value of approximately EUR 520 million on a fully diluted basis.
TraceLink unveils Product Information Manager for its digital information sharing platform
12 Jul 2018
Product Information Manager addresses a broad range of use cases, beginning with saleable returns.Read more
Stability studies trends
10 Jul 2018
Dr Ramesh Jagadeesan, Sr. Director - Analytical Development at Recipharm, speaks to CPhI Online on the trends and challenges involved with conducting stability studies for firms that supply to multiple countries, and the advantages of using a contracto...Read more
Recipharm launches standalone serialisation service
5 Jul 2018
Company will be able to add 2D codes, human-readable text and tamper evidence to pre-packed medicines using existing equipment across its facilities.Read more
CPhI Worldwide opens entries for 15th Annual Pharma Awards
5 Jul 2018
Winners will be announced live at the Gala Ceremony in Madrid with over 500 of Pharma’s top executives.Read more
Catalent to acquire Juniper Pharmaceuticals
5 Jul 2018
$133 million deal adds European Early Development Center of Excellence to global network.Read more
Insights in lyophilization science
4 Jul 2018
The latest developments in process development, nucleation control, scale-up of freeze drying cycles and development in lyophilization technology.Read more
Bosch to sell its packaging business
4 Jul 2018
Packaging technology is not a core Bosch business.Read more
Plasticell leads gene therapy manufacturing consortium
3 Jul 2018
Consortium to develop advanced technologies for the manufacturing of ex vivo gene therapies.Read more
Forté Pharma strengthens its leadership in weight control in France
1 Jul 2018
Company consolidated as one of the leading laboratories in weight control thanks to the development of its existing range and new launches.Read more
I Holland woos exhibition visitors with new tabletting technologies
28 Jun 2018
Company's Wear Indicator Layer attracts the most attention.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation